Clinical practice guideline for the evaluation and management of patients with severe aortic stenosis for the Peruvian Social Security

Guía de práctica clínica para la evaluación y el tratamiento de pacientes con estenosis aórtica severa en el Seguro Social del Perú

David Gálvez-Caballero¹, Jorge Huaringa-Marcelo², César Conde-Vela³, Christoper A. Alarcón-Ruíz⁴, José Ernesto Fernández-Chingue⁵, Alvaro Taype-Rondan⁶, Hector van Dyck-Arbulú⁶, Gladys Martha Espinoza-Rivas⁷, Julio Alberto Morón-Castro⁸, Jorge Luis Ortega-Díaz⁹, Zoila Ivonne Rodríguez-Urteaga² and Raúl Timaná-Ruíz∗

¹Department of Clinical Cardiology, Instituto Nacional Cardiovascular (INCOR), EsSalud; ²Clinical Practice Guidelines, Drug Safety Monitoring and Techno-surveillance Directorate, Institute for Health Technologies Evaluation and Research, EsSalud; ³Interventional Cardiology Department, INCOR, EsSalud; ⁴Research Unit for the Generation and Synthesis of Evidence in Health, Universidad San Ignacio de Loyola, Lima; ⁵Faculty of Human Medicine, Universidad San Martín de Porres, Chiclayo; ⁶Department of Cardiovascular Surgery; ⁷Department of Non-Interventional Cardiology; ⁸Institutional Directorate; ⁹Department of Diagnosis and Treatment Aid. INCOR, EsSalud, Lima, Peru

Abstract

Introduction: This article summarizes the clinical practice guide (CPG) for the evaluation and management of patients with severe aortic stenosis in the Social Security of Peru (EsSalud). Objective: To provide clinical evidence-based recommendations for the evaluation and management of patients with severe aortic stenosis in the EsSalud. Methods: A local guideline development group (local GDG) was established, including medical specialists and methodologists. The local GDG formulated 7 clinical questions to be answered by this CPG. Systematic searches of systematic reviews and, when it was considered pertinent, primary studies, were conducted in PubMed during 2018. The evidence to answer each of the posed clinical questions was selected. The quality of the evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. In periodic work meetings, the local GDG used the GRADE methodology to review the evidence and formulate the recommendations, points of good clinical practice, and the flowchart of evaluation and management. Finally, the CPG was approved with Resolution N.° 47 – IETS – ESSALUD – 2018. Results: This CPG addressed 7 clinical questions regarding two issues: the initial evaluation and the management of severe aortic stenosis. Based on these questions, 9 recommendations (1 strong recommendation and 8 weak recommendations), 16 points of good clinical practice, and 1 flowchart were formulated. Conclusion: This article summarizess the methodology and evidence-based conclusions from the CPG for the evaluation and management of patients with severe aortic stenosis in the EsSalud.

Key words: Severe aortic stenosis. Clinical practice guideline. GRADE. Evidence- based medicine. Peru.

Correspondence:
*Raúl Timaná-Ruíz
Jirón Domingo Cueto, 109, Jesús María
C.P. 15072, Lima, Perú
E-mail: raul.timana@essalud.gob.pe

Available online: 09-08-2019
Arch Cardiol Mex (Eng). 2019;89(1):53-67
DOI: 10.24875/ACME.M19000009
www.archivoscardiologia.com

2604-7063 © 2018 Instituto Nacional de Cardiología Ignacio Chávez. Published by Permanyer México. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

In aortic stenosis, a decrease in the aortic valve area progressively occurs, which generates a restriction in left ventricle (LV) blood outflow to the aorta. The most common causes are degenerative, rheumatic and congenital. Degenerative aortic stenosis occurs in 5% of adults older than 65 years, out of which 11% have severe aortic stenosis. It is considered “severe” when the aortic valve orifice is smaller than 1 cm² and mean aortic transvalvular gradient is equal to or higher than 40 mmHg.

Patients with severe aortic stenosis are initially asymptomatic; however, in the course of the pathology they develop dyspnea, angina and syncope, which cause quality of life deterioration and increased mortality. One-year risk of sudden death in asymptomatic patients is 1%, and in symptomatic individuals this risk increases to 3-5% at six months. Aortic valve replacement surgery has been shown to achieve a significant mortality reduction in these patients. In patients with contraindication or high risk for aortic valve replacement surgery, percutaneous aortic valve prosthesis implantation is a safe and effective alternative.

Thus, severe aortic stenosis is a high-risk condition, which requires interdisciplinary management to reduce morbidity and mortality. The Clinical Practice Guidelines, Drug Safety Monitoring and Techno-surveillance Directorate of the Institute for Health Technologies Evaluation and Research (IETSI – Instituto de Evaluación de Tecnologías en Salud e Investigación), together with specialists of the National Cardiovascular Institute (INCOR – Instituto Nacional Cardiovascular) and the Peruvian Social Security (EsSalud), developed these evidence-based clinical practice guidelines (CPG), which issued recommendations and good clinical practice (GCP) points for the evaluation and treatment of patients with severe aortic stenosis. The present article is a summary of said CPG.

Methodology

The procedure followed for the development of these CPGs is described in detail on its extended version, which can be downloaded from the EsSalud IETSI website (http://www.essalud.gob.pe/ietsi/guias_pract_clin.html). In brief, the following methodology was applied:

– Formation of the local guideline development group (Local GDG). It was comprised by methodologists and cardiology, interventional cardiology and cardiovascular surgery specialist physicians.

– Formulation of questions. In accordance with this CPGs’ objectives and scope, the Local GDG formulated seven clinical questions (Table 1), each one with one or more PICO (Population, Intervention, Comparator, Outcome) questions. In turn, each PICO question could have one or more outcomes of interest.

– Search and selection of evidence. For each PICO question, evidence was searched and selected. In this, during January-February 2018, a search was made for systematic reviews (SR) published as scientific articles (through systematic searches in PubMed) or performed as part of a previous CPG.
document (through a systematic search of CPGs on the subject) (Appendix 1). When SRs of acceptable quality were found, one was chosen for decision making, which was updated when the local GDG considered it necessary. When no RS of acceptable quality was found, a new search was made for primary studies.

- Quality of evidence evaluation. Quality of evidence for each outcome of each PICO question was considered high, moderate, low or very low (Table 2). To assess the quality of evidence, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was followed and GRADE evidence profile tables were used (Appendix 2). Finally, the PICO question was assigned the lowest level of quality reached by any of these outcomes.

- Formulation of recommendations. The local GDG reviewed the selected evidence for each clinical question in periodic meetings and issued strong or weak recommendations (Table 2) using the GRADE methodology. For this, the following was considered: 1) benefits and harms of the options; 2) patient values and preferences; 3) acceptability by health professionals; 4) feasibility of the options at EsSalud health establishments, and 5) use of resources. After discussing these criteria for each question, the local GDG formulated recommendations by consensus or by simple majority. In addition, the local GDG formulated GCP points, usually based on clinical experience.

- Review by external experts. The present CPGs were reviewed in meetings with specialist physician representatives of other institutions and decision-makers. Furthermore, the extended version was electronically submitted to external experts (mentioned in the acknowledgments section) for its review. The local GDG took the results of these reviews into account for amending the final recommendations.

- CPG approval. These CPGs were approved to be used in EsSalud, with Resolution No. 47 - IETSI - ES-SALUD - 2018.

- CPG updating. This GPC has a validity of three years. As the end of this period approaches, a literature SR will be carried out for its update, after which it will be decided whether this CPG is updated or if a new version is created.

**Recommendations**

The present CPG addressed seven clinical questions, related to two subjects: severe aortic stenosis initial evaluation and treatment. Based on these questions, nine recommendations were formulated (one strong recommendation and eight weak recommendations), 16 good clinical practice points and a flow chart (Table 3 and Fig. 1).

In patients with aortic stenosis, the physician should decide which criteria will be used to establish the severe aortic stenosis diagnosis (question 1). Then, the physician should decide on treatment, and for that he/she must determine which surgical risk grading system will be used (question 2), how will he/she treat asymptomatic patients (question 3) and when will he/she choose surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) in symptomatic patients (question 4). If performing a TAVR is decided, the access route must be decided (question 5).

<table>
<thead>
<tr>
<th>Topic</th>
<th>Clinical questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial assessment</td>
<td>Question 1. In patients with aortic stenosis, which severity classification system should be used?</td>
</tr>
<tr>
<td>Treatment</td>
<td>Question 2: In patients with severe aortic stenosis, which surgical risk grading system should be used: STS or EuroSCORE II? Question 3: In patients with severe asymptomatic aortic stenosis, should valve replacement be early performed or wait for the patient to develop symptoms? Question 4: In patients with severe symptomatic aortic stenosis, should SAVR or TAVR be performed? Question 5: In patients with severe aortic stenosis in whom performing TAVR is decided, which should be the first-choice access route for TAVR? Question 6: In patients with severe aortic stenosis in whom performing TAVR is decided and who, in addition, have severe coronary artery disease, should PCI be performed? Question 7: Should a Heart Team be formed that decides the treatment of patients with severe aortic stenosis?</td>
</tr>
</tbody>
</table>

**Table 1. Addressed clinical questions**

**EuroSCORE II: European System for Cardiac Operative Risk Evaluation II; PCI: percutaneous coronary intervention; SAVR: surgical aortic valve replacement; STS: Society of Thoracic Surgeons Risk Score; TAVR: transcatheter aortic valve replacement.**

55
and the possibility of carrying out or not a percutaneous coronary intervention if the patient also has severe coronary artery disease (question 6). Finally, for the management of patients with severe aortic stenosis, it is necessary to determine if a group of experts or Heart Team will be required (question 7).

Below, the recommendations for each clinical question, as well as a summary of the rationale to arrive to each recommendation, are presented.

**Question 1. In patients with aortic stenosis, which severity classification system should be used?**

**Recommendations and good clinical practice points**

To classify aortic stenosis-diagnosed patients into mild, moderate or severe aortic stenosis, using the aortic stenosis classification system proposed by the American Heart Association/American College of Cardiology (AHA/ACC) 2014 guidelines (not modified in the 2017 update) is recommended. GCP.

**From evidence to decision**

Severity should be determined in all patients with aortic stenosis. This classification has prognostic and therapeutic implications. In patients with mild or moderate aortic stenosis, clinical observation and periodic monitoring shall be carried out. In those with severe symptomatic aortic stenosis, valve replacement shall be evaluated.

Different systems have been developed to classify the severity of patients with aortic stenosis. Our systematic search found classifications in the AHA/ACC 2006 and 2014, 2017-updated CPGs, in the European Society of Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) 2017 CPGs and in the Brazilian Society of Cardiology/Inter-American Society of Cardiology (BSC/IASC Brazil) 2011 CPGs; in addition to a classification proposed by Lancelotti.

No studies were found that have compared the different types of classification between each other. Therefore, no recommendations were issued, but GCP points.

**Question 2. In patients with severe aortic stenosis, which surgical risk grading system score should be used: STS or EuroSCORE II?**

**Recommendations and good clinical practice points**

In patients with severe aortic stenosis with SAVR or TAVR indication, we suggest applying the European System for Cardiac Operative Risk Evaluation II (Table 2).

<table>
<thead>
<tr>
<th>Table 2. Meaning of the levels of quality of evidence and strength of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quality of evidence</strong></td>
</tr>
<tr>
<td>(⊕⊕⊕⊕) High</td>
</tr>
<tr>
<td>The true effect is highly likely to be similar to the estimated effect</td>
</tr>
<tr>
<td>(⊕⊕⊕) Moderate</td>
</tr>
<tr>
<td>The true effect is moderately likely to be similar to the estimated effect, but it is possible for it to be substantially different</td>
</tr>
<tr>
<td>(⊕⊕) Low</td>
</tr>
<tr>
<td>Our confidence in the estimated effect is limited. The true effect might be substantially different from the estimated effect</td>
</tr>
<tr>
<td>(⊕) Very low</td>
</tr>
<tr>
<td>We have very little confidence in the estimated effect. The true effect is highly likely to be substantially different from the estimated effect</td>
</tr>
</tbody>
</table>

**Implication of the strength of recommendation**

- **Strong recommendation (for or against)**
  The local GDG believes that all or nearly all professionals that review available evidence would follow this recommendation. In the recommendation formulation, the term “recommended” is used.

- **Weak recommendation (for or against)**
  The local GDG believes that most professionals that review available evidence would follow this recommendation, but a group of professionals might not follow it. In the recommendation formulation, the term “suggested” is used.

Local GDG: Local guideline developing group.
### Table 3. Full list of recommendations

<table>
<thead>
<tr>
<th>Question N°</th>
<th>Statement</th>
<th>Type*</th>
<th>Strength and direction†</th>
<th>Quality of evidence‡</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initial assessment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>To classify patients diagnosed with aortic stenosis in mild, moderate or severe aortic stenosis, using the aortic stenosis classification system proposed by the 2014 AHA/ACC guidelines (not modified in AHA/ACC 2017 update) is recommended.</td>
<td>GCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>In patients with severe aortic stenosis with SAVR or TAVR indication, we suggest applying the EuroSCORE II and STS scoring systems to assess valve replacement surgical risk.</td>
<td>R</td>
<td>Weak in favor</td>
<td>Very low (⊕⊕⊕⊕)</td>
</tr>
<tr>
<td></td>
<td>Patients with severe aortic stenosis shall be classified according to their surgical risk as:</td>
<td>GCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– Low risk. STS or EuroSCORE II &lt; 4%, without frailty or comorbidities and with no hindrances for the specific procedure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– Intermediate risk. STS or EuroSCORE II between 4 and 8%, with no more than slight frailty or compromise of no more than one major organ/system that will not improve postoperatively, and minimum hindrances for the specific procedure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– High risk. STS or EuroSCORE II &gt; 8%, or with moderate to severe frailty, with compromise of no more than 2 major organs/systems that will not improve postoperatively, or a possible hindrance to the specific procedure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– Prohibitive risk. Preoperative one-year mortality and morbidity risk &gt; 50%, with compromise of ≥ 3 major organs/systems that will not improve postoperatively, severe frailty, or a severe hindrance to the specific procedure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>In patients with severe asymptomatic aortic stenosis, we suggest not systematically performing early aortic valve replacement.</td>
<td>R</td>
<td>Weak in favor</td>
<td>Very low (⊕⊕⊕⊕)</td>
</tr>
<tr>
<td></td>
<td>Patients with severe asymptomatic aortic stenosis shall be scheduled for early valve replacement if they have any of the following conditions:</td>
<td>GCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– Patients with LVEF &lt; 50%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– Aortic valve severe calcification (≥ 3,000 AU in males or ≥ 1,600 AU in females)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– Rapid increase in transaortic velocity (&gt; 0.3 m/s increase per year)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– Highly severe aortic stenosis (transaortic velocity ≥ 5.5 m/s or mean gradient pressure ≥ 60 mmHg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– Adverse hemodynamic changes (symptoms or decrease in blood pressure) during stress test</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– Severe pulmonary hypertension with no other explanation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patients with severe asymptomatic aortic stenosis should be clinically assessed every 6 months or when the patient exhibits disease-related symptoms (dyspnea, angina or syncpoe).</td>
<td>GCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patients with severe asymptomatic aortic stenosis who start developing symptoms shall be assessed for risk stratification and aortic valve replacement scheduling</td>
<td>GCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>In patients with severe symptomatic aortic stenosis with life expectancy of more than one year, aortic valve replacement should be performed</td>
<td>GCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>In patients with severe symptomatic aortic stenosis with life expectancy of more than one year and low surgical risk, we suggest SAVR performance as first treatment choice</td>
<td>R</td>
<td>Weak in favor</td>
<td>Very low (⊕⊕⊕⊕)</td>
</tr>
<tr>
<td></td>
<td>In patients with severe symptomatic aortic stenosis with life expectancy of more than one year and intermediate surgical risk, we suggest SAVR performance as first treatment option</td>
<td>R</td>
<td>Weak in favor</td>
<td>Very low (⊕⊕⊕⊕)</td>
</tr>
<tr>
<td></td>
<td>In patients with severe symptomatic aortic stenosis with life expectancy of more than one year and high surgical risk, we suggest the performance of SAVR or TAVR</td>
<td>R</td>
<td>Weak in favor</td>
<td>Very low (⊕⊕⊕⊕)</td>
</tr>
</tbody>
</table>

(Continues)
In patients with severe symptomatic aortic stenosis with life expectancy of more than one year that are classified as inoperable we suggest the performance of TAVR as first treatment option

<table>
<thead>
<tr>
<th>Question N°</th>
<th>Statement</th>
<th>Type*</th>
<th>Strength and direction†</th>
<th>Quality of evidence †</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>In patients with severe symptomatic aortic stenosis with life expectancy of more than one year that are classified as inoperable we suggest the performance of TAVR as first treatment option</td>
<td>R</td>
<td>Strong in favor</td>
<td>Moderate (⊕⊝⊝⊝)</td>
</tr>
<tr>
<td>5</td>
<td>In patients with severe symptomatic aortic stenosis with life expectancy of more than one year and low surgical risk, consider SAVR as first-choice treatment, without the need for prior evaluation by the Heart Team</td>
<td>GCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>In patients with severe symptomatic aortic stenosis with life expectancy of more than one year and who have intermediate surgical risk (who in addition have criteria of frailty, very advanced age, inadequate body mass index or a severe comorbidity), high surgical risk, or who are considered inoperable: have an evaluation made by the Heart Team to decide their treatment</td>
<td>GCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>In patients with severe symptomatic aortic stenosis, in situations of emergency, acute decompensation or non-cardiac surgery, and who have valve replacement indication: consider percutaneous valvotomy as bridging therapy for SAVR or TAVR</td>
<td>GPC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>In patients with severe symptomatic aortic stenosis who have a life expectancy of less than one year, contraindicate SAVR and TAVR and provide palliative treatment</td>
<td>GPC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>In patients with severe symptomatic aortic stenosis undergoing TAVR, follow the procedures established by procedural guidelines or local protocols</td>
<td>GPC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Disagreements on risk stratification or treatment will be decided by the Heart Team</td>
<td>GPC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>In patients with severe aortic stenosis in whom performing TAVR is decided, we recommend the first choice approach to be transfemoral</td>
<td>R</td>
<td>Weak in favor</td>
<td>Very low (⊕⊝⊝⊝)</td>
</tr>
<tr>
<td>6</td>
<td>In patients with severe aortic stenosis in whom the performance of TAVR is decided, and who in addition have severe coronary artery disease, we suggest the performance of PCI</td>
<td>R</td>
<td>Weak in favor</td>
<td>Very low (⊕⊝⊝⊝)</td>
</tr>
<tr>
<td>7</td>
<td>Health facilities that perform cardiovascular surgery in patients with severe aortic stenosis with intermediate, high and/or prohibitive surgical risk shall put together a Heart Team that will be in charge of deciding patient treatment</td>
<td>GCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>The Heart Team should be made up of at least: one clinical cardiologist with experience in valvular pathology; one cardiologist expert in cardiovascular imaging; one interventional cardiologist; one cardiovascular surgeon with experience in valvular pathology</td>
<td>GCP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

EuroSCORE II: European System for Cardiac Operative Risk Evaluation II; LVEF: Left Ventricle Ejection Fraction; PCI: percutaneous coronary intervention; SAVR: surgical aortic valve replacement; STS: Society of Thoracic Surgeons Risk Score; TAVR: transcatheter aortic valve replacement. *Recommendation (R) or good clinical practice (GPC) point. †Strength, direction and quality of evidence are only established for recommendations, not for GCP points.
**Figure 1.** Severe aortic stenosis evaluation and treatment flow chart. AHA: American Heart Association; EuroSCORE II: European System for Cardiac Operative Risk Evaluation II; LVEF: left ventricle ejection fraction; BMI: body mass index; PCI: percutaneous coronary intervention; SxR: surgical risk; SAVR: surgical aortic valve replacement; STS: Society of Thoracic Surgeons Risk Score; TAVR: transthoracic aortic valve replacement.

*Severe coronary disease: ≥ 70% reduction in the diameter of any major coronary artery, or ≥ 50% reduction in the diameter of the left coronary artery trunk.
**Table 4. Aortic stenosis stages according to AHA/ACC (2014)**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
<th>Valvular anatomy</th>
<th>Aortic valve hemodynamic measurements</th>
<th>Hemodynamic consequences</th>
<th>Symptoms</th>
<th>LVEF</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Ca++ Mobility</td>
<td>Essential criteria</td>
<td>Additional measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>At risk of AS</td>
<td>+ Normal</td>
<td>Aortic $V_{max} &lt; 2 \text{ m/s}$</td>
<td>-</td>
<td>None</td>
<td>Normal</td>
</tr>
<tr>
<td>B</td>
<td>Progressive AS</td>
<td>++ ↓↓</td>
<td>Mild AS: aortic $V_{max} 2.0-2.9 \text{ m/s}$ or mean $\Delta P &lt; 20 \text{ mmHg}$ Moderate AS: aortic $V_{max} 3.0-3.9 \text{ m/s}$ or mean $\Delta P &lt; 20-39 \text{ mmHg}$</td>
<td>-</td>
<td>None</td>
<td>Normal</td>
</tr>
<tr>
<td>C</td>
<td>Severe asymptomatic AS</td>
<td>+++ ↓↓↓</td>
<td>Severe AS: aortic $V_{max} \geq 4 \text{ m/s}$ or mean $\Delta P \geq 40 \text{ mmHg}$ Highly severe AS: aortic $V_{max} \geq 5.0 \text{ m/s}$ or mean $\Delta P \geq 60 \text{ mmHg}$</td>
<td>AVA $\leq 1.0 \text{ cm}^2$ (or AVAi $\leq 0.6 \text{ cm}^2/\text{m}^2$)</td>
<td>LV diastolic dysfunction – Mild LV hypertrophy</td>
<td>None</td>
</tr>
<tr>
<td>C1</td>
<td>Severe asymptomatic AS with LV dysfunction</td>
<td>+++ ↓↓↓</td>
<td>Severe AS: aortic $V_{max} \geq 4 \text{ m/s}$ or mean $\Delta P \geq 40 \text{ mmHg}$</td>
<td>AVA $\leq 1.0 \text{ cm}^2$ (or AVAi $\leq 0.6 \text{ cm}^2/\text{m}^2$)</td>
<td>None</td>
<td>&lt; 50%</td>
</tr>
<tr>
<td>C2</td>
<td>Severe asymptomatic AS with LV dysfunction</td>
<td>+++ ↓↓↓</td>
<td>Severe AS: aortic $V_{max} \geq 4 \text{ m/s}$ or mean $\Delta P \geq 40 \text{ mmHg}$</td>
<td>AVA $\leq 1.0 \text{ cm}^2$ (or AVAi $\leq 0.6 \text{ cm}^2/\text{m}^2$)</td>
<td>None</td>
<td>&lt; 50%</td>
</tr>
<tr>
<td>D</td>
<td>Severe symptomatic AS</td>
<td>++++ ↓↓↓</td>
<td>Aortic $V_{max} \geq 4 \text{ m/s}$ or mean $\Delta P \geq 40 \text{ mmHg}$</td>
<td>AVA $\leq 1.0 \text{ cm}^2$ (or AVAi $\leq 0.6 \text{ cm}^2/\text{m}^2$), but it can be larger with combined AS/AI</td>
<td>LV diastolic dysfunction – LV hypertrophy</td>
<td>– Dyspnea on exertion or exercise decreased tolerance – Exercise-induced angina – Exercise-triggered syncope or pre-syncope</td>
</tr>
<tr>
<td>D1</td>
<td>Severe symptomatic AS with high gradient</td>
<td>++++ ↓↓↓</td>
<td>Aortic $V_{max} \geq 4 \text{ m/s}$ or mean $\Delta P &lt; 40 \text{ mmHg}$ at rest</td>
<td>Dobutamine stress test shows an AVA $\leq 1.0 \text{ cm}^2$ with aortic $V_{max} \geq 4 \text{ m/s}$ with any flow</td>
<td>LV diastolic dysfunction – LV hypertrophy</td>
<td>Heart failure – Angina</td>
</tr>
<tr>
<td>D2</td>
<td>Severe symptomatic AS with low flow/low gradient and reduced LVEF</td>
<td>++++ ↓↓↓</td>
<td>AVA $\leq 1.0 \text{ cm}^2$ with aortic $V_{max} &lt; 4 \text{ m/s}$ or mean $\Delta P &lt; 40 \text{ mmHg}$ at rest</td>
<td>AVAi $\leq 0.6 \text{ cm}^2/\text{m}^2$ and &lt; 35 mL/m²</td>
<td>LV wall increased thickness – Small LV chamber – Restrictive diastolic filling</td>
<td>Heart failure – Angina</td>
</tr>
</tbody>
</table>

AI: aortic insufficiency; AS: aortic stenosis; AWA: aortic valve area; AVAi: aortic valve area index; BP: blood pressure; Ca++: valve calcification; LV: left ventricle; LVEF: left ventricle ejection fraction; mean$\Delta P$: transaortic pressures mean difference; PHT: pulmonary hypertension; transaortic $V_{max}$: maximum transaortic velocity.
(EuroSCORE II) score and the Society of Thoracic Surgeons Risk Score (STS) to assess surgical risk for valve replacement. Weak recommendation in favor, very low quality of evidence (⊕ ⊙ ⊙ ⊙).

- Patients with severe aortic stenosis will be classified according to their surgical risk as:
  - Low risk. STS or EuroSCORE II < 4%, without frailty or comorbidities and with no hindrances to the specific procedure.
  - Intermediate risk. STS or EuroSCORE II between 4 and 8%, with no more than slight frailty or compromise of no more than one major organ/system that will not improve postoperatively and minimum hindrances to the specific procedure.
  - High risk. STS or EuroSCORE II > 8% or with moderate to severe frailty, with compromise of no more than two major organs/systems that will not improve postoperatively or possible hindrance to the specific procedure.
  - Prohibitive risk. Preoperative mortality and morbidity risk > 50% at one year, with compromise of three or more major organs/systems that will not improve postoperatively, severe frailty or severe hindrance to the specific procedure. GCP.

**From evidence to decision**

Patients with severe aortic stenosis require aortic valve replacement treatment, and it is therefore necessary for surgical risk to be assessed in these patients. The most widespread and known surgical risk scoring systems are EuroSCORE II and STS. Both predict mortality and morbidity risk after valve replacement surgery. EuroSCORE II is available at www.euroscore.org and STS at http://riskcalc.sts.org/stswebriskcalc/#/calculate.

To answer this question, three subpopulations were assessed: patients intervened with SAVR, patients operated with TAVR and patients who were operated with either intervention indistinctly. SRs of observational studies for each subpopulation were found. In patients undergoing SAVR, one SR (5 studies, n = 11,791) concluded that STS overestimates mortality. In patients undergoing TAVR, one SR (24 studies, n = 12,346) concluded that EuroSCORE II underestimates mortality. In patients undergoing SAVR or TAVR, one SR (10 studies, n = 13,856) concluded that STS overestimates mortality.

Owing to these heterogeneous results, making a recommendation in favor of applying both scoring systems for making the decision on which intervention to perform was decided. Given that the quality of evidence is very low and that not all doctors would accept such a measure, and neither would patients do, since it would imply a larger number of evaluations and time, assigning a weak strength of recommendation was decided.

**Good clinical practice approach**

Using the cutoff points proposed by the Singh meta-analysis (2017) and the ESC/EACTS guidelines was decided to classify patients with severe aortic stenosis at low risk (< 4%), intermediate risk (4-8%) and high risk (> 8%), both with STS and with EuroSCORE II. Finally, adopting the consensus recommendation of the ACC experts was decided in order to include other criteria such as frailty, comorbidities and hindrances to the specific procedure.

**Question 3. In patients with severe asymptomatic aortic stenosis, should aortic valve replacement be early performed or wait for the patient to develop symptoms?**

**Recommendations and good clinical practice points**

- In patients with severe asymptomatic aortic stenosis, we suggest not systematically performing early aortic valve replacement. Weak recommendation against, very low quality of evidence (⊕ ⊙ ⊙ ⊙).
- Patients with severe asymptomatic aortic stenosis shall be scheduled for early valve replacement if they have any of the following conditions:
  - Patients with left ventricle ejection fraction (LVEF) <50%.
  - Aortic valve severe calcification (≥ 3,000 Agatston units [AU] in men or ≥ 1,600 AU in women).
  - Rapid increase in transaortic valve velocity (> 0.3 m/s increase per year).
  - Highly severe aortic stenosis (transaortic velocity ≥ 5.5 m/s or mean pressure gradient ≥ 60 mmHg).
  - Adverse hemodynamic changes (symptoms or blood pressure decrease) during stress testing.
  - Severe pulmonary hypertension with no other explanation. GCP.
- Patients with severe asymptomatic aortic stenosis should be clinically evaluated every six months or when the patient experiences symptoms related to the disease (dyspnea, angina or syncope). GCP.
Patients with severe asymptomatic aortic stenosis that start developing symptoms will be assessed for risk stratification and aortic valve replacement scheduling. GCP.

**From evidence to decision**

A patient with severe asymptomatic aortic stenosis is defined as a patient who does not report symptoms. Approximately more than half the patients with severe aortic stenosis are asymptomatic at diagnosis. Treatment of these patients is controversial.

One SR (4 observational studies, n = 1,300) compared early aortic valve replacement versus conservative treatment and reported similar all-cause mortality or cardiovascular cause mortality. This would indicate that the short-term benefit of performing early interventions in this group of patients is probably small. However, the lack of randomized clinical trials (RCTs) hinders clearly establishing the potential benefit of early intervention.

A potential benefit of early intervention could be the delay in symptom onset and the possibility of definitive treatment in patients who cannot return for consultation. In our institution, availability of surgery shifts for aortic valve replacement is limited, and this intervention should therefore be carried out in patients with severe symptomatic aortic stenosis, since they are at higher mortality risk than those who are asymptomatic. Therefore, formulating a recommendation against systematically practicing early aortic valve replacement was decided. Given that the quality of evidence is very low, that patient acceptability is low because they are asymptomatic, that few physicians would agree to precociously carry out the procedure and that feasibility is therefore low, assigning a weak strength of recommendation was decided.

**Good clinical practice approach**

Based on two CPGs recommendations, some subgroups of asymptomatic patients may be considered for early aortic valve replacement, due to the increased risk of mortality. Furthermore, consensus was reached on that patients with severe asymptomatic aortic stenosis should be evaluated every six months or when they experience symptoms related to the disease. In addition, it was deemed that when these patients develop symptoms, they should undergo valve replacement intervention.

**Question 4. In patients with severe symptomatic stenosis aortic, should surgical aortic valve replacement or percutaneous aortic valve replacement be performed?**

**Recommendations and good clinical practice points**

- In patients with severe symptomatic aortic stenosis with life expectancy of more than one year, aortic valve replacement should be performed. GCP.
- In patients with severe symptomatic aortic stenosis with life expectancy of more than one year and low surgical risk, we suggest the performance of SAVR as the first treatment option. Weaker recommendation in favor, very low quality of evidence.
- In patients with severe symptomatic aortic stenosis with life expectancy of more than one year and intermediate surgical risk, we suggest the performance of SAVR or TAVR. Weak recommendation in favor, very low quality of evidence.
- In patients with severe symptomatic aortic stenosis with life expectancy of more than one year and high surgical risk, SAVR should be considered as first treatment option, without the need of previous assessment by the Heart Team. GCP.
- In patients with severe symptomatic aortic stenosis with life expectancy of more than one year and who are classified as inoperable, we suggest the performance of TAVR as first treatment option. Strong recommendation in favor, moderate quality of evidence.
- In patients with severe symptomatic aortic stenosis who have frailty criteria, very advanced age, inadequate body mass index or a severe comorbidity, high surgical risk or who are considered inoperable: assessment by the Heart Team should be performed to decide their treatment. GCP.
- In patients with severe symptomatic aortic stenosis, in emergency situations, acute decompensation or non-cardiac surgery and who have valve replacement indication: consider performing percutaneous valvotomy as bridge therapy for SAVR or TAVR. GCP.
In patients with severe symptomatic aortic stenosis who have a life expectancy of less than one year, contraindicate SAVR and TAVR and provide palliative treatment. GCP.

In patients with severe symptomatic aortic stenosis undergoing TAVR, follow the procedures established in procedural guidelines or local protocols. GCP.

Disagreements in risk stratification or treatment will be decided by the Heart Team. GCP.

From evidence to decision

This question addresses the management of patients with severe symptomatic aortic stenosis. In these patients, SAVR or TAVR should be performed.

For this question, the following subpopulations were assessed: patients with low, intermediate and high surgical risk and inoperable patients. A patient is defined at low, intermediate and high surgical risk when he/she obtains values < 4, 4-8 and > 8%, respectively, on any of the proposed indexes (EuroSCORE II or STS). An inoperable patient is defined as that who has a pre-operative mortality and morbidity risk > 50% at one year, with compromise of ≥ 3 major organs/systems that will not improve postoperatively, severe frailty or a severe hindrance to the specific procedure.

In patients with low surgical risk, one SR (2 RCTs and 4 observational studies, n = 3,484) found that TAVR, in comparison with SAVR, has similar all-cause 30 days and 1-year mortality, higher late mortality, lower risk of acute kidney injury, similar risk of stroke, higher risk for major vascular complications and need for permanent pacemaker implantation. Based on these heterogeneous results, and since TAVR was deemed to require greater use of resources, formulating a recommendation in favor of SAVR was decided. Given that the quality of evidence is low, and that patients and doctors do not entirely accept it, this recommendation had a weak strength.

In patients with intermediate surgical risk, the SRs by Singh (3 RCTs and 5 observational studies, n = 4,752) and Sardar (2 RCTs and 5 observational studies, n = 4,601) found that TAVR, in comparison with SAVR, has similar 30-day and 1-year all-cause mortality, similar stroke risk, similar myocardial infarction risk, lower acute kidney injury risk, lower major bleeding risk and greater need for permanent pacemaker implantation. Based on these heterogeneous results, in addition to the fact that the balance of benefits and risks of the intervention did not favor the use of TAVR, despite the fact that this intervention requires higher use of resources, formulating a recommendation in favor of SAVR was decided. Since the quality of evidence is low, it would not be entirely accepted by doctors and patients, which would hinder its feasibility; therefore, assigning weak strength to the recommendation was decided.

In patients with high surgical risk, the PARTNER 1 RCT (n = 699), with results published at one year, three years and five years of follow-up, TAVR, in comparison SAVR, was found to have similar all-cause mortality at 30 days, one year, three and five years, higher risk of stroke, similar risk of transient ischemic attack, lower risk of acute kidney failure, similar risk of acute myocardial infarction, higher risk of major vascular complication and lower risk of major bleeding. Since the quality of evidence was low, and since doctors and patients would prefer TAVR, but owing to its low feasibility and excessive use of resources, formulating a weak recommendation for using any of the interventions (SAVR or TAVR) was decided. In inoperable patients but with life expectancy of more than one year, there are also results available from the PARTNER 1 RCT (n = 358), published at one, two, three and five years of follow-up; TAVR was found to have lower all-cause mortality than medical treatment. Therefore, formulating a recommendation in favor of TAVR was decided. Given that the quality of evidence was moderate and that it would be accepted by both doctors and patients, this recommendation had a strong strength of recommendation.

Good clinical practice approach

In patients with severe symptomatic aortic stenosis with life expectancy of more one year, it was agreed that performing aortic valve replacement should be sought in order to relieve symptoms and lessen mortality. In addition, in patients with life expectancy of less than one year, carrying out SAVR or TAVR was considered not to be justified.

By consensus, it was established that a multidisciplinary team, or Heart Team, should decide the treatment of all patients with severe symptomatic aortic stenosis deemed inoperable or at high surgical risk, as well as of those with surgical intermediate risk who are also frail or have advanced age, inadequate body mass index or a severe comorbidity.

Aortic valvuloplasty performance was considered as a temporary treatment for some patients who have a valve replacement indication and that find themselves in emergency situations. It should be kept in mind that this treatment is effective during 6 or 12 months, since later the aortic valve develops stenosis again.
– Finally, it was considered important to note that TAVR should be performed following procedural guidelines or local protocols and that disagreements on risk stratification or treatment should be assessed by the Heart Team.

**Question 5. In patients with severe aortic stenosis in whom performing percutaneous aortic valve replacement is decided, what should be the first-choice access route for it?**

**Recommendations and good clinical practice points**

– In patients with severe aortic stenosis in whom performing TAVR is decided, we recommend that first-choice access route should be transfemoral. Weak recommendation in favor, very low quality of evidence ⊕⊕⊕⊕.

– When the transfemoral route is not feasible, the Heart Team will evaluate each particular case to define the possible use of other approaches such as through the subclavian artery, or the transapical or transaortic routes. The Heart Team will make this decision based on invasive and/or non-invasive imaging studies. GCP.

**From evidence to decision**

Once TAVR performance has been decided, the access route for transcatheter aortic valve implantation should be established; the most common routes in our setting are: transfemoral (TF), through the subclavian artery (TSc) and transapical (TA).

To answer this question, two comparisons were assessed: TF vs. TSc and TF vs. TA. As for the comparison between TF and TSc, one SR (6 observational studies, n = 4,504) found that 30-day mortality, one-year mortality, major complications at 30 days and acute kidney injury were similar between both groups37. However, favoring the TF approach was decided because it is easier and more accepted by professionals.

Regarding the comparison between TF and TA, the SRs that were considered found that 30-day mortality38 and acute kidney injury39 were lower in the TF group, while vascular complications were higher in the TF group40; and one-year mortality40, definitive pacemaker implantation and 30-day bleeding were similar in both groups41. Thirty-day mortality and acute kidney injury were considered to be the most clinically relevant outcomes and, hence, favoring the TF approach was decided.

Therefore, due to its benefits, and especially to a lower risk of complications, formulating a recommendation in favor of the use of the TF route was decided. Given that the quality of evidence is very low, that the route of access for TAVR may depend on anatomical factors, and due to certain comorbidities, as well as to the fact that not all doctors and patients find always using this route of access acceptable, formulating a weak recommendation was decided.

**Good clinical practice approach**

If the TF approach cannot be performed, it was deemed that other approaches can be chosen, according to availability and training. This decision should be taken by the Heart Team based on invasive and/or non-invasive imaging studies.

**Question 6. In patients with severe aortic stenosis in whom performing percutaneous aortic valve replacement is decided and who, in addition, have severe coronary artery disease, should percutaneous coronary intervention be performed?**

**Recommendations and good clinical practice points**

– In patients with severe aortic stenosis in whom performing TAVR is decided and who, in addition, have severe coronary artery disease, we suggest performing percutaneous coronary intervention (PCI). Weak recommendation in favor, very low quality of evidence ⊕⊕⊕⊕.

– In patients with severe aortic stenosis in whom performing TAVR is decided and who, in addition, have severe coronary artery disease for which performing PCI has been decided, we suggest that PCI should be carried out prior to TAVR. Weak recommendation in favor, very low quality of evidence ⊕⊕⊕⊕.

– Performing myocardial revascularization (PCI for those undergoing TAVR or coronary artery bypass graft for those undergoing SAVR) is recommended when severe coronary artery disease is found (≥ 70% reduction in the diameter of any major coronary artery or ≥ 50% reduction in the diameter of the left coronary artery trunk). GCP.

**From evidence to decision**

Approximately half the patients with severe aortic stenosis have chronic coronary heart disease6. In patients
who will undergo TAVR and that also have severe coronary disease, whether PCI is to be performed should be decided, and if so, whether it will be performed in advance or at the same moment (concomitant) than TAVR.

With regard to the decision to perform PCI or not, one SR (7 observational studies, n = 1,631) compared patients undergoing TAVR with PCI and undergoing TAVR without PCI, and found that 30-day, 6-month and one-year mortality, cardiovascular mortality, as well as vascular access site complications, were similar. This evidence suggests that PCI for severe coronary disease might be carried out without major risks in these patients. Therefore, formulating a recommendation in favor of PCI performance was decided.

Regarding the decision on whether to perform PCI previously or concomitant with TAVR, one SR (7 observational studies, n = 1,631) that compared patients undergoing PCI prior and concomitant with TAVR, found that kidney failure incidence was higher in the concomitant group, whereas 30-day mortality and vascular access site complications were similar between groups. In that same sense, an observational study (n = 65) found that mortality was similar between these groups. Due to the lower risk of kidney failure and the complexity of performing PCI concomitant with TAVR in our context, formulating a recommendation in favor of the performance of PCI prior to TAVR was decided.

In view of the very low quality of evidence, regular acceptability by doctors and patients, and the low feasibility of performing this procedure, assigning a weak strength of recommendation was decided.

**Good clinical practice approach**

Adopting the AHA/ACC 2014 guidelines GCP point on the need for perform myocardial revascularization (PCI for those undergoing TAVR or coronary artery bypass graft for those undergoing SAVR) in those patients with severe coronary artery disease (defined as $\geq 70\%$ reduction in the diameter of any major coronary artery or $\geq 50\%$ reduction in the diameter of the left coronary artery trunk) was considered pertinent.

**Question 7. Should a Heart Team that decides the treatment of the patient with severe aortic stenosis be put together?**

**Recommendations and good clinical practice points**

- Health facilities that perform cardiovascular surgery in patients with severe aortic stenosis at intermediate, high and/or prohibitive surgical risk should form a Heart Team that will be in charge of deciding patient treatment. GCP.
- The Heart Team should comprise at least:
  - One clinical cardiologist with experience in valvular pathology.
  - One cardiologist expert in cardiovascular imaging.
  - One interventional cardiologist.
  - One cardiovascular surgeon with experience in valvular pathology. GCP.

**From evidence to decision**

The Heart Team is a multidisciplinary and collaborative team whose purpose is to make decisions about the treatment of patients with severe aortic stenosis with intermediate, high or prohibitive risk. In the performed search no studies were found that have assessed the Heart Team efficacy, which is why no recommendations were issued, but GCP points were established by consensus.

**Good clinical practice approach**

It was deemed that health establishments that carry out cardiac surgery in patients with severe aortic valve stenosis and that have high surgical risk need to decide between the performance of SAVR and TAVR in the Heart Team. For the formation of the Heart Team, recommendations of other authors were considered, as well as feasibility according to the local context. This way, it was established by consensus that the Heart Team should be comprised by at least: one clinical cardiologist with experience in valvular pathology, one cardiologist expert in cardiovascular imaging, one interventional cardiologist certified in TAVR and one cardiovascular surgeon with experience in valvular pathology.

**Authorship contributions**

All authors participated in the development of these guidelines. JHM, ATR, CAAR and JEFC were responsible for the systematic searches and quality assessment of the studies for each question. All authors participated in the discussion of the retrieved studies and in the formulation of recommendations and GCP points. All authors reviewed and approved the manuscript final version.

**Conflicts of interest**

Cesar Nicolás Conde Vela has given talks about left coronary trunk angioplasty and radial access on
November 2017 for TERUMO (a company that manufactures interventional cardiology devices and supplies). The rest of the authors declare not having any conflicts of interest, financial or not, related with the topics described in this article.

**Funding**

The Clinical Practice Guidelines for evaluation and treatment of patients with severe aortic stenosis at the Peruvian Social Security (EsSalud) have been funded by the Institute for Health Technologies Evaluation and Research, EsSalud, of Peru.

**Ethical responsibilities**

**Protection of people and animals.** The authors declare that no experiments have been conducted on humans or animals for this investigation.

**Confidentiality of data.** The authors declare having followed the protocols of their work center on the publication of patient data.

**Right to privacy and informed consent.** The authors declare that no patient data appear in this article.

**Supplementary Data**

Supplementary data are available at Revista Archivos de Cardiología de México online (http://www.desarrollo-archivoscardio.mi/index.php). These data are provided by the corresponding author and published online for the benefit of the reader. The contents of supplementary data are the sole responsibility of the authors.

**Acknowledgements**

We thank the following people for the review they made of the present guidelines:

José María Hernández García, Director of the Hemodynamics and Interventional Cardiology Unit, Hospital Universitario Virgen de la Victoria, Malaga, Spain.

José Armando Mangione, interventional cardiologist and senior scientific researcher, Director of the of Interventional Cardiology area, Hospital Sao Joaquim Beneficencia Portuguesa, São Paulo, Brazil.

**References**


